Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of pegfilgrastim (Jinyouli) for prevention of chemotherapy-induced neutropenia in ovarian cancer
ChiCTR1900027961Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in neutropenia and febrile neutropenia (FN), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Incidence rate of febrile neutropenia. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR1900027961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027961.